Ahmadzadehfar, H., Essler, M., Schafers, M., & Rahbar, K. (2016). Radioligand therapy with (177)Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use. Nucl Med Biol, 43(12), 835. https://doi.org/10.1016/j.nucmedbio.2016.08.003
Azad, A. A., Eigl, B. J., Murray, R. N., Kollmannsberger, C., & Chi, K. N. (2015). Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol, 67(1), 23-29. https://doi.org/10.1016/j.eururo.2014.06.045
Baccala, A., Sercia, L., Li, J., Heston, W., & Zhou, M. (2007). Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology, 70(2), 385-390. https://doi.org/10.1016/j.urology.2007.03.025
Badrising, S. K., van der Noort, V., van den Eertwegh, A. J., Hamberg, P., van Oort, I. M., van den Berg, H. P., . . . Bergman, A. M. (2016). Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. Prostate, 76(1), 32-40. https://doi.org/10.1002/pros.23094
Bander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., & Goldsmith, S. J. (2005). Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol, 23(21), 4591-4601. https://doi.org/10.1200/jco.2005.05.160
Baum, R. P., Kulkarni, H. R., & Albers, P. (2017). Theranostics: PSMA ligands for molecular imaging and radionuclide therapy of advanced prostate cancer. Onkologe, 23(8), 597‐608. https://doi.org/10.1007/s00761-017-0246-2
Bouchelouche, K., Choyke, P. L., & Capala, J. (2010). Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med, 9(44), 55-61.
Brasso, K., Thomsen, F. B., Schrader, A. J., Schmid, S. C., Lorente, D., Retz, M., . . . de Bono, J. (2015). Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. Eur Urol, 68(2), 317-324. https://doi.org/10.1016/j.eururo.2014.07.028
Bräuer, A., Grubert, L. S., Roll, W., Schrader, A. J., Schäfers, M., Bögemann, M., & Rahbar, K. (2017). 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 44(10), 1663-1670. https://doi.org/10.1007/s00259-017-3751-z
Caffo, O., De Giorgi, U., Fratino, L., Alesini, D., Zagonel, V., Facchini, G., . . . Galligioni, E. (2015). Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol, 68(1), 147-153. https://doi.org/10.1016/j.eururo.2014.10.014
D'Amico, A. V., Whittington, R., Malkowicz, B., Schnall, M., Schultz, D., Cote, K., . . . Wein, A. (2000). Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol, 164(3 Pt 1), 759-763.
Davies, R. S., Smith, C., & Lester, J. F. (2016). Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer. Anticancer Res, 36(4), 1799-1803.
de Bono, J. S., Chowdhury, S., Feyerabend, S., Elliott, T., Grande, E., Melhem-Bertrandt, A., . . . Fizazi, K. (2018). Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for >/=24 weeks in Europe. Eur Urol, 74(1), 37-45. https://doi.org/10.1016/j.eururo.2017.07.035
Emmett, L., Crumbaker, M., Ho, B., Willowson, K., Eu, P., Ratnayake, L., . . . Joshua, A. M. (2019). Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. Clinical Genitourinary Cancer, 17(1), 15-22. https://doi.org/10.1016/j.clgc.2018.09.014
Fendler, W. P., Kratochwil, C., Ahmadzadehfar, H., Rahbar, K., Baum, R. P., Schmidt, M., . . . Krause, B. J. (2016). [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin, 55(3), 123-128. (Original work published Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom.)
Heck, M. M., Retz, M., D'Alessandria, C., Rauscher, I., Scheidhauer, K., Maurer, T., . . . Eiber, M. (2016). Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J Urol, 196(2), 382-391. https://doi.org/10.1016/j.juro.2016.02.2969
Kulkarni, H. R., Singh, A., Schuchardt, C., Langbein, T., Pienta, K. J., & Baum, R. P. (2017). Lu-177 PSMA radioligand therapy might prolong survival in metastatic castration-resistant prostate cancer: results from a single center over 4 years. European Journal of Nuclear Medicine and Molecular Imaging, 44(2), S204‐. https://doi.org/10.1007/s00259-017-3822-1
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P., . . . Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj, 339, b2700. https://doi.org/10.1136/bmj.b2700
Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., . . . Massard, C. (2013). Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol, 24(7), 1807-1812. https://doi.org/10.1093/annonc/mdt136
Moody, T. E., Spraitzar, C. L., Eisenhart, E., & Tully, S. (2017). The american urological association's prostate cancer screening guideline: Which cancers will be missed in average-risk men aged 40 to 54 years? Reviews in urology, 19(2), 106-112. https://doi.org/10.3909/riu0748
Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N. (2013). Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol, 24(7), 1802-1807. https://doi.org/10.1093/annonc/mdt138
Pezaro, C. J., Omlin, A. G., Altavilla, A., Lorente, D., Ferraldeschi, R., Bianchini, D., . . . Attard, G. (2014). Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol, 66(3), 459-465. https://doi.org/10.1016/j.eururo.2013.11.044
Rahbar, K., Afshar-Oromieh, A., Jadvar, H., & Ahmadzadehfar, H. (2018). PSMA Theranostics: Current Status and Future Directions. Molecular imaging, 17, 1536012118776068-1536012118776068. https://doi.org/10.1177/1536012118776068
Rahbar, K., Boegemann, M., Yordanova, A., Eveslage, M., Schafers, M., Essler, M., & Ahmadzadehfar, H. (2018). PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging, 45(1), 12-19. https://doi.org/10.1007/s00259-017-3848-4
Rahbar, K., Bogeman, M., Yordanova, A., Eveslage, M., Schafers, M., Essler, M., & Ahmadzadehfar, H. (2018). Delayed response after repeated (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging, 45(2), 243-246. https://doi.org/10.1007/s00259-017-3877-z
Scarpa, L., Buxbaum, S., Kendler, D., Fink, K., Bektic, J., Gruber, L., . . . Virgolini, I. (2017). The (68)Ga/(177)Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates. Eur J Nucl Med Mol Imaging, 44(5), 788-800. https://doi.org/10.1007/s00259-016-3609-9